Amneal to Participate in Upcoming Investor Conferences

BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financial Officer, will participate in following upcoming investor conferences:

Piper Sandler 2025 Healthcare Conference
Date: December 3, 2025
Fireside Chat: Wednesday, December 3, 2025, at 9:30AM EST
Location: New York, NY

J.P. Morgan 2026 Healthcare Conference
Date: January 12-15, 2026
Presentation: Tuesday, January 13, 2026, at 4:30PM PST
Location: San Francisco, CA

A webcast of the presentations will be available on Amneal’s Investor Relations website at www.amneal.com/investors. Replays will be available for a limited time following each event.

About Amneal

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 290 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com and follow us on LinkedIn.

Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com

Staff

Recent Posts

Owlet Launches TGA-Approved Dream Sock™ in Australia & New Zealand, Expanding International Footprint and Bringing Trusted Pediatric Health Monitoring to More Families Worldwide

TGA approval enables regional launch of Owlet’s clinically validated, award-winning infant health monitor; Owlet360™ subscription…

2 hours ago

CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines

Concludes Distribution Agreement with Gore® for VIABIL® in the United States and Canada, Effective January…

2 hours ago

TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company…

2 hours ago

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the…

2 hours ago